Functional Ionic Liquids and Organic Salts for Pharmaceutical Applications

Luis BRANCO^1
1LAQV-REQUIMTE, Caparica, Portugal

Nowadays, the possibility to discovery sustainable and efficient solutions related to costly problems from pharmaceutical industry such as polymorphism, drug diversification and as modulators of Biopharmaceutical Drug Classification System (BCS) is essential. The combination between different pharmaceutical drugs with biocompatible counter-ions seems a very attractive research topic to be explored[1,2]. In last years, our research team already reported examples of pharmaceutical ionic liquids and organic salts (API-OSILs) based on anti-inflammatory (e.g. ibuprofen)[3]; antibiotics (beta-lactams and fluoroquinolones)[4,5]; anti-tumoral (bisphosphonates)[6-8] and anti-tuberculostatic (isoniazid, mefloquine)[9,10] with significant advantages comparing with original APIs. It is important to note that some beta-lactam antibiotics as API-ILs reveals a very high anti-bacterial activity especially against resistant bacteria (RDIC values >100 and 1000) which agrees with theoretical prediction of drug improvement [4,5]. Although these recent developments, API-OSILs seem to be a suitable drug delivery system for APIs by improving bioavailability (solubility, permeability) and eliminate polymorphism[11].
Herein, we will present our latest developments in the field of API-OSILs including the functionalization with silica nanoparticles [12]. Some of API-OSILs are very promising for further application as ionic formulations for pharmaceutic industry.  
 
Acknowledgments: The authors thank the financial support by FCT – MCTES (PTDC/QUI-QOR/32406/2017; UID/QUI/00100/2013, UID/QUI/50006/2013 and IF/0041/2013/CP1161/CT00), MAR2020 (MAR-02.01.01-FEAMP-0042; INOVA4AQUA project) and Solchemar company.
 
References
[1] I. M. Marrucho; L. C. Branco; L. P. N. Rebelo, Annual Rev. Chem. Biom. Eng. 2014, 5, 527.
[2] I. C. B. Martins; M. C. Oliveira; H. P. Diogo; L. C. Branco; M. T. Duarte, ChemSusChem 2019, 10, 1360.
[3] M. M. Santos; L. R. Raposo; G. V. S. M. Carrera; A. Costa; M. Dionísio; P. V. Baptista; A. R. Fernandes; L. C. Branco, ChemMedChem 2019, 14, 907.
[4] M. M. Santos; C. Alves; J. Silva; C. Florindo; A. Costa; Z. Petrovski; I.M. Marrucho; R. Pedrosa; L. C. Branco, Pharmaceutics 2020, 12, 694.
[5] R. Ferraz; D. Silva; A. R. Dias; V. Dias; M. M. Santos; L. Pinheiro; C. Prudêncio; J. P. Noronha; Z. Petrovski; L. C. Branco, Pharmaceutics 2020, 12, 221.
[6] S. Teixeira; M. M. Santos; R. Ferraz; C. Prudêncio; M. H. Fernandes; J. Costa?Rodrigues; L. C. Branco, ChemMedChem 2019, 14, 1767.
[7] S. Teixeira; M. M. Santos; M. H. Fernandes; J. Costa-Rodrigues; L. C. Branco, Pharmaceutics 2020, 12, 293.
[8] S. Teixeira; M. M. Santos; L. C. Branco; J. Costa-Rodrigues,
[9] F. Santos; L. C. Branco; A. R. C. Duarte, Pharmaceutics 2020, 12, 952.
[10] D. Silva; M. V. C. Lopes; Z. Petrovski; M. M. Santos; J. P. Santos; S. F. Yamada-Ogatta; M. L. F. Bispo; M. V. N. de Souza; A. R. C. Duarte; M. C. S. Lourenço; R. S. B. Gonçalves; L. C. Branco, Molecules 2022, 27, 5167.
[11] I. C. B. Martins; A. Forte; H. P. Diogo; L. R. Raposo; P. V. Baptista; A. R. Fernandes; L. C. Branco; M. T. Duarte, Chemistry Methods 2022, 2, e202100104.
[12] B. de Juan Mora; L. Filipe; A. Forte; M. M. Santos; C. Alves; F. Teodoro; R. Pedrosa; M. Ribeiro Carrott; L. C. Branco; S. Gago, Pharmaceutics 2021, 13, 218.